Regeneronvs.Vertex Pharmaceuticals
REGN vs VRTX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Vertex Pharmaceuticals is about 1.7× larger than Regeneron by market cap; Regeneron trades at the lower P/E (17.6 vs 29.0); year to date, Vertex Pharmaceuticals leads (+11.0% vs −4.2%).
Side by side
| REGN | VRTX | |
|---|---|---|
| Market cap | $76.1B | $128B |
| Price | $746.54 | $510.08 |
| Today | +0.9% | +1.4% |
| Return YTD | −4.2% | +11.0% |
| Return 1Y | +31.2% | +19.5% |
| Since June 26, 2026 | +18.0% | +3.8% |
| P/E | 17.6 | 29.0 |
| P/S | 4.9 | 10.1 |
| P/B | 2.4 | 6.3 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
RegeneronREGN
Antibody engineering underpins the whole portfolio, from Eylea in ophthalmology to Dupixent, partnered with Sanofi, in immunology. Oncology is the newer front.
Full REGN profile →Vertex PharmaceuticalsVRTX
Cystic fibrosis medicines carry the business. The newer work sits in pain treatment and in cell and gene therapy, where Casgevy belongs.
Full VRTX profile →More REGN & VRTX comparisons
Other head-to-heads in the Biotech & innovation segment.